B细胞淋巴因子-2抑制剂venetoclax的药理作用与临床评价

Pharmacological and clinical evaluation of venetoclax-BCL-2 inhibitor in the treatment of chronic lymphocytic leukemia

Venetoclax是一种口服的B细胞淋巴因子-2选择性抑制剂,主要用于治疗染色体异常删除突变del17p、且曾至少接受过1次化疗的慢性淋巴细胞白血病。常见的不良反应为腹泻、恶心、上呼吸道感染、中性粒细胞减少及疲劳等。本文对其药理作用、药动学、临床评价、安全性、用法用量和药物相互作用进行综述。

Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2. It is mainly indicated for the treatment of patients with chronic lymphocytic leukemia（ CLL） with 17p deletion,who have received at least one prior therapy. The most common adverse events were diarrhea,nausea,upper respiratory tract infection,neutropenia,and fatigue. The pharmacology,pharmacokinetics,clinical research,safety,dosage,and drug interactions of venetoclax were reviewed in this paper.